GrafixCORE®: Open-Label Study to Evaluate the Safety and Efficacy of GrafixCORE® for Complex Diabetic Foot Wounds

Overview

A multicenter, open-label, single-arm study to evaluate the safety and efficacy of GrafixCORE® for the treatment of complex diabetic foot wounds with exposed tendon and/or bone.

Full Title of Study: “A Multicenter, Open-label, Single-Arm Study to Evaluate the Safety and Efficacy of GrafixCORE® for the Treatment of Complex Diabetic Foot Wounds With Exposed Tendon and/or Bone”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: October 2015

Interventions

  • Other: Grafix®
    • The treatment indication is for complex diabetic foot wounds with exposed tendon and/or bone that can accommodate up to three 5cm x 5cm pieces of Grafix®. Patients will be treated for up to 16 weeks. Patients will be evaluated at screening and then weekly throughout the study or until wound closure.

Arms, Groups and Cohorts

  • Other: Open-Label
    • Grafix®: Cryopreserved Placental Membrane

Clinical Trial Outcome Measures

Primary Measures

  • 100% granulation of wound as determined by the investigator
    • Time Frame: Up to 16 weeks after the Initial Treatment Visit

Secondary Measures

  • Time to 100% granulation
    • Time Frame: Up to 16 weeks after the Initial Treatment Visit
  • Number of applications of Grafix®
    • Time Frame: Up to 16 weeks after the Initial Treatment Visit
  • Measurement of percent wound area reduction as determined by the investigator
    • Time Frame: Up to 16 weeks after the Initial Treatment Visit
  • Closure of wound defined by 100% re-epithelialization
    • Time Frame: Up to 16 weeks after the Initial Treatment Visit

Participating in This Clinical Trial

Inclusion Criteria

1. Between 18 years and 85 years of age inclusive, as of the date of screening

2. Confirmed diagnosis of Type I or Type II Diabetes

3. Index wound graded in the Texas Classification System as Grade II-III, Stage A or C (without active infection)

4. Wound is located on the foot below the malleoli

5. Wound accommodates up to three (3) 5 cm x 5 cm pieces of GrafixCORE® that completely cover the wound

6. Patient's wound extends through the dermis and into subcutaneous tissue with evidence of exposed muscle, tendon, bone, and/or joint capsule

7. Patient has adequate circulation to the foot as documented by either:

  • Ankle Brachial Index (ABI) ≥ 0.5 and ≤ 1.2, or
  • In patients with non-compressible ankle vessels, a Toe BP ≥ 40 mmHg or TcPO2 > 30 mmHg, or
  • Skin perfusion pressure > 30 mmHg

Exclusion Criteria

1. Index Wound is of non-diabetic pathophysiology

2. Gangrene is present on any part of the affected foot

3. Index Wound is over a Charcot deformity

4. The longest dimension of the Index Wound exceeds 15 cm at the Baseline Visit

5. Patient has a glycated hemoglobin A1 (HbA1c) level of >14%

6. Requiring intravenous (IV) antibiotics to treat the index wound infection at enrollment

7. Patient has a wound within 15cm of the Index Ulcer identified for study consideration

8. Patient is receiving oral or parenteral corticosteroids, immunosuppressive or cytotoxic agents

9. Patient is Human Immunodeficiency Virus (HIV) positive or has Acquired Immune Deficiency Syndrome (AIDS)

10. Current evidence of osteomyelitis, cellulitis, or other evidence of infection including fever or pus drainage from the wound site

11. Patient has active malignancy other than non-melanoma skin cancer

12. Patient's random blood sugar is >450 mg/dl at screening

13. Patient has untreated alcohol or substance abuse at the time of screening, or is deemed to be non-adherent to the protocol by the Investigator

14. Pregnant women

15. Patient is currently enrolled or participated in another investigational device, drug, or biological trial within 30 days of screening

16. Patient has allergy to primary or secondary dressing materials used in this trial

17. Patient has had within the last 14 days, or is currently undergoing, or is planning for wound treatments with enzymes, growth factors, living skin, dermal substitutes or other advanced biological therapies

18. In the opinion of the Investigator, the patient is unsuitable for participation in the study

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 85 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Osiris Therapeutics
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.